Qiming Venture Partners said that its portfolio company Structure Therapeutics Inc. (GPCR), a clinical stage global biopharmaceutical company focusing on novel oral small molecule therapeutics, successfully debuts on Nasdaq on February 3 Beijing Time. It issued at $15.00 per ADS, opened at $25.00 per ADS and up by 66.67%, representing a market cap of $915 million.
Founded in 2006, Qiming Venture Partners is a China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.
For comments and feedback contact: editorial@rttnews.com
Business News